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(mCRC) was not recommended in the UK (until June 2009), but accepted under a 
price volume agreement scheme with prior authorization in Italy, and without restric-
tion in France and Germany. These products are funded on top of DRG costs in 
France, but not in other countries. We reviewed how such differences might affect 
usage of TRZ and CTX in France, Germany, Italy and UK. METHODS: Data on 
drug utilization from June 2006 to July 2009 were extracted from the Synovate Oncol-
ogy Monitor, an ongoing database tracking prescribing of anti-cancer therapies. 
Sample sizes varied between countries and indications, from 1700 to 6200 patients. 
RESULTS: Proportions of patients receiving TRZ from July 08 to June 09 ranged 
from 9% (UK) to 16% (Italy) in early BC, 12% (Italy) to 19% (France) in ﬁrst-line 
advanced BC and 10% (France) to 34% (Italy) in second-line (irrespective of HER2 
screening). For CTX, utilization rates ranged from 0% (UK) to 13% (France) in ﬁrst-
line and 2% (UK) to 19% (Italy) in second-line. Utilization of TRZ increased over 
time in early stage BC. Utilization of CTX was stable in France, increased in Germany 
and decreased in Italy. Dosages and patient proﬁles were comparable across countries. 
CONCLUSIONS: Funding on top of DRG does not appear to increase drug uptake. 
Health technology assessment conclusions inﬂuence utilization strongly. When access 
is granted, administrative constraints may reduce ﬁrst-line utilization to the beneﬁt of 
second-line. This should be considered when decisions are made about access to 
innovative medicine.
HT3
MULTICRITERIA DECISION ANALYSIS (MCDA) FOR DRUG COVERAGE 
DECISION BY A PUBLIC HEALTH PLAN: CASE STUDY OF TRAMADOL 
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OBJECTIVES: To ﬁeld-test a decision support framework (EVIDEM) and explore its 
utility to a drug advisory committee using tramadol for chronic non-cancer pain 
(CNCP) as a case study. METHODS: The EVIDEM framework includes a multicri-
teria decision analyses matrix (MCDA) composed of 15 quantiﬁable components of 
decision including six domains (disease impact, context of intervention, intervention 
outcomes, type of beneﬁt, economics and quality of evidence) and a qualitative tool 
including six components of decision regarding ethical considerations, system capacity 
and political/historical context. A synthesized health technology assessment (HTA) 
report tailored to investigate each component of decision was developed for tramadol 
for CNCP. MCDA weights and scores, and qualitative considerations were provided 
by each committee member to evaluate tramadol from a public health plan perspective. 
RESULTS: The committee estimated the value of tramadol for CNCP at 44% (min: 
36%, max: 61%) of maximum value on the MCDA scale. Main contributors to the 
MCDA value estimate were size of population affected by disease (15% of total), 
disease severity (11%) and impact on adverse event expenditures (8%). Limited 
improvement in efﬁcacy, safety and patient reported outcomes were not signiﬁcant 
contributors to MCDA value. For a majority of committee members, ethical consid-
erations on utility, efﬁciency and fairness had respectively a positive, neutral and 
negative impact on the value of tramadol. CONCLUSIONS: By systematizing consid-
eration of all components of decision and underlying evidence, the framework allows 
consistent approach to evaluating health care interventions. Further testing and valida-
tion is needed to advance MCDA approaches in health care decisionmaking.
HT4
PRAGMATIC CLINICAL TRIALS FOR DRUG APPROVAL: IS IT REALISTIC?
Mohr P1, Sonnad S2, Mullins CD3, Whicher D1, Goldsack J2, Tunis SR1
1Center for Medical Technology Policy, Baltimore, MD, USA, 2University of Pennsylvania, 
Philadelphia, PA, USA, 3University of Maryland School of Pharmacy, Baltimore, MD, USA
BACKGROUND: Patients, clinicians, payers and policymakers increasingly are inter-
ested in understanding comparative “real world” effectiveness of pharmaceutical 
products, often noting that traditional clinical trials performed for regulatory approval 
may not address important questions about the full range of beneﬁts and harms of 
new drugs used in typical clinical settings. While more pragmatic designs are used for 
post-marketing studies, to date, no group formally has considered their utility and 
feasibility for regulatory approval trials. METHODS: In 2009, the Center for Medical 
Technology Policy convened an expert stakeholder working group to characterize 
recurring gaps in evidence that generally are not addressed in regulatory trials, explore 
the reasons for those shortcomings, and generate ideas for improving methods to make 
these trials more informative for patient and physician choices and reimbursement and 
coverage decisions. The working group included representatives from pharmaceutical 
companies, regulatory bodies, private and public payers, academics, consumers, and 
technology assessment organizations. Using discussions from this meeting and contin-
ued engagement of the working group over time, we developed a conceptual, meth-
odological and policy framework to improve the design and implementation of 
pragmatic regulatory trials. RESULTS: There emerged greater than anticipated con-
sensus among the regulators and payers participating in the working group that some 
pragmatic features are desirable and feasible to include in regulatory trials. The 
working group developed eight basic principles for making regulatory trials more 
pragmatic, covering the engagement of post-regulatory decision makers early in the 
design process to methods for designing more efﬁcient trials. CONCLUSIONS: The 
optimal approach to pragmatic trials may not involve incorporating all possible 
pragmatic features, as are typically associated with large, simple trials. Some domains 
of pragmatism are more important to payers than others and any incremental move-
ment toward more pragmatic designs may be not only highly valuable, but feasible.
PODIUM SESSION I: RESEARCH ON PRO METHODS  
(INCLUDING UTILITIES)
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OBJECTIVES: Analysts typically take as “ﬁxed” the underlying tariff scoring function 
of a given utility instrument when conducting probabilistic sensitivity analysis, ignor-
ing an important source of uncertainty. An “off-the-shelf” catalogue of EQ-5D scores 
from a nationally representative U.S. population has recently been published. The 
current study aims to incorporate the uncertainty in the underlying U.S. EQ-5D tariff 
function by estimating conﬁdence intervals around estimates from the catalogue. 
METHODS: The Medical Expenditure Panel Survey (MEPS), a general population 
survey in the U.S., was pooled (2000, 2001, 2002 and 2003) to create a sample of 
79,524 adults with valid EQ-5D responses. Chronic conditions were classiﬁed by 
ICD-9 codes and Clinical Classiﬁcation Category (CCC) codes. Censored least abso-
lute deviations (CLAD) regression methods were used to estimate the marginal disutil-
ity of each condition controlling for age, comorbidity, gender, race, ethnicity, income 
and education. US tariffs for the EQ-5D (Shaw) were applied to questionnaire 
responses. However, instead of taking the US EQ-5D tariff as a “ﬁxed” function of 
the questionnaire responses, 500 bootstraps were conducted drawing from a distribu-
tion of possible EQ-5D tariffs based on the standard errors from the original scoring 
estimation. RESULTS: A catalogue of marginal disutility (EQ-5D) scores for each 
chronic ICD-9 and CCC code were estimated 500 times based on the distribution of 
possible EQ-5D tariffs. The 95% range of these potential marginal disutilities is 
presented and compared. CONCLUSIONS: Scores and marginal disutilities for a wide 
variety of chronic ICD-9 and CCC codes can be used to estimate QALYs in cost-
effectiveness analyses. This research provides a range of values around each marginal 
disutility in the catalogue of “off-the-shelf” EQ-5D scores. Uncertainty in the underly-
ing US EQ-5D estimation tariff is incorporated in these ranges to encourage better 
understanding of the inherent uncertainty in EQ-5D estimates and to facilitate future 
probabilistic sensitivity analyses.
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OBJECTIVES: To evaluate the measurement properties of the EQ-5D proﬁle aug-
mented with its 0–100 mm visual analogue scale (VAS) and a 5-point summary self-
rating of health (SRH). METHODS: We used data from 4,001 adults from the 2003 
MEPS who had ≥1 of 7 most prevalent chronic conditions and completed the EQ-5D, 
VAS, and SRH. The original 101 VAS categories were collapsed into a 9-category 
item with sufﬁcient responses in each category. Five SRH categories included “excel-
lent”, “very good”, “good”, “fair” and “poor”. The Rasch rating scale and partial 
credit models were used to calibrate the EQ-5D and the single items, respectively. 
Calibrations were conducted using 4 different combinations: EQ-5D alone; EQ-
5D+SRH; EQ-5D+VAS, and EQ-5D+SRH+VAS. Model goodness-of-ﬁt was assessed 
in each disease group using INFIT mean squares (≤1.40). Principal Component Analy-
sis of Rasch Residuals was used to conﬁrm dimensionality examining the proportion 
of total variance explained by Rasch scale, person measures and item measures, 
respectively. RESULTS: Respondents were predominantly white, female, middle aged 
and suffered most commonly from hypertension (32%), diabetes (17%) and depres-
sion (15%). EQ-5D item “anxiety/depression” consistently showed misﬁt to the model 
across 7 conditions when EQ-5D was evaluated alone. The inclusion of VAS and/or 
SRH not only improved model ﬁt, but also increased overall variances explained, and 
improved overall distribution of persons and items along the latent health trait. Speciﬁ-
cally, when both items were included, 4 groups showed good model ﬁt (mean squares 
≤1.40). Consistently across all groups, VAS captured more person measures while 
SRH captured more item measures. CONCLUSIONS: The EQ-5D’s measurement 
qualities are enhanced by the inclusion of VAS/SRH, which captures integral aspect 
of self-valuations on health that are possibly overlooked by the EQ-5D. The EQ-
5D+VAS+SRH may serve as a suitable measurement framework for deriving popula-
tion preference-weights. Consequently, a new valuation algorithm is called for.
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Background Despite the growing importance of the EQ-5D descriptive system as a 
basis for the valuation of QALYs in cost-utility analysis, for most countries there are 
no EQ-5D social value sets. Researchers and policy makers wishing to use the EQ-5D 
descriptive system in a country for which there is no value set are advised to use one 
from a nearby or ‘similar’ population. Factors other than geographic proximity can 
affect the relative values of EQ-5D states. Objective This study explores the links 
